Evaluation of the Philips Lifeline CareSage Risk Assessment System
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03126565|
Recruitment Status : Completed
First Posted : April 24, 2017
Last Update Posted : September 1, 2020
|Condition or disease||Intervention/treatment||Phase|
|Multimorbidity||Other: Lifeline CareSage Flagging||Not Applicable|
The growing elderly population and rising rates of costly chronic disease have led to the development of preventative homecare management opportunities to improve health outcomes and reduce the number of patients who enter costly inpatient care. Partners HealthCare at Home (PHH) is a preventative homecare management system which offers general care as well as specialized services to help patients and their loved ones manage chronic conditions at home. Such continuity of care is achieved through a multidisciplinary clinical team and the integration of telemonitoring into the patient's care plan.
The Philips Lifeline Personal Emergency Response Service (PERS), a wearable button device worn on the wrist or as a pendant, is a telemonitoring device available to patients receiving care through PHH. When the patient presses the button, the patient is immediately connected with a Lifeline response agent. Philips Lifeline (PLL) has developed CareSage, a predictive analytics engine that combines continuous monitoring with predictive analytics. The clinical interface (CareSage platform) helps care teams monitor the patient's calculated risk scores for emergency transport. The algorithm used by this integrated risk assessment system was originally developed after studying a large cohort of the PERS subscribers (N = ~600,000). In Phase 1 of this study the algorithm was validated among a cohort (N = 3,335) of PHH patients to predict emergency transports in this population (AUC = .76).
In Phase 2 of this study, the investigators will conduct a prospective, randomized trial of 370 patients to assess the effect of the risk assessment CareSage platform and PHH tailored interventions on the rate of readmissions, quality of life, and the overall cost of medical care. The investigators hypothesize that a multidisciplinary intervention approach could significantly reduce the healthcare resource utilization in patient at high risk for hospitalization. The intervention will flag those patients at the highest risk for hospital transport, alert the patient's care team that an intervention may be needed, thereby targeting care at high risk patients who are most likely to get readmitted. By predicting which patients are at high risk of hospital transport which may lead to hospitalization, targeting interventions at those patients and engaging patients with their care team, the investigators hope to reduce readmissions, hospital days, and rates of mortality in high risk patients.
The goal of this 2-arm randomized controlled study is to assess the impact of the CareSage risk assessment platform on 90- and 180-day Emergency Department (ED) visits in a cohort of PHH patients. All patients will receive the PERS device and be followed for a total of 9 months, including an initial 3-month observation period and followed by a 6-month intervention period. At the beginning of the observation period (baseline), enrolled patients will be randomized into 2 groups: the Intervention Group or the Control Group. During the observation period the CareSage algorithm will calibrate using patient data (both groups) collected during this interval from the PERS device. Then, during the intervention period, patients in the intervention group will be actively monitored by the CareSage algorithm and will receive tailored PHH interventions if flagged as being at high risk for emergency transport. Patients in the control group will receive care as usual during the intervention period. All data collected during the study will be used to further strengthen the CareSage algorithm developed in the Phase I of this study.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||370 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Evaluating the Impact of an Integrated Risk Assessment System (Philips Lifeline Personal Emergency Response Service) on Healthcare Utilization|
|Actual Study Start Date :||May 19, 2017|
|Actual Primary Completion Date :||April 16, 2019|
|Actual Study Completion Date :||November 30, 2019|
Experimental: Group A
This group will include a cohort of 185 participants who will be monitored by the CareSage risk assessment platform. Tailored interventions, using a Stepped-Care Approach, will be targeted to patients flagged as high risk for emergency transport during the 6-month intervention period.
Other: Lifeline CareSage Flagging
Patients in the intervention group will receive active monitoring by the CareSage risk assessment platform and clinical interface, including nurse triage calls and tailored PHH interventions. Beginning at month 4, the CareSage algorithm will assess patients' risk for emergency transport every 30 days. Patients identified as high risk will receive nurse triage calls and, depending on their needs, tailored care according to a stepped-care approach. The principal goals will be to reinforce the patients' education, ensure compliance with medications and diet, and identify recurrent symptoms amenable to treatment on an outpatient basis to avoid readmissions
No Intervention: Group B
This group will include a cohort of 185 participants where study staff will not see if patients are flagged by the CareSage risk assessment platform as being at high or low risk for emergency transport during the 6-month intervention period. Patients will continue to receive care as usual.
- Number of participants who visit the emergency department 90 and 180 days after the three month observational period and assessed by reviewing the medical records [ Time Frame: 9 months after study enrollment ]To assess the impact of the CareSage risk assessment platform and tailored PHH intervention on the 90- and 180- day ED visits.
- Emergency Transport use [ Time Frame: 9 months after study enrollment ]Patient usage of emergency transport
- 30-, 90- and 180- day readmissions [ Time Frame: 9 months after study enrollment ]Data pertaining to the 30-day readmissions will be collected in the intervention period (6 months).
- Total number of avoidable hospital admissions using Center for Medicare and Medicaid Services (CMS) criteria [ Time Frame: 9 months after study enrollment ]Total number of avoidable hospital admissions
- Total medical expenses attributable to the avoidable admissions [ Time Frame: 9 months after study enrollment ]Total medical expenses attributable to the avoidable admissions
- Mortality rates [ Time Frame: 9 months after study enrollment ]Patient deaths
- Time to readmission [ Time Frame: 9 months after study enrollment ]Length of time before patient was readmitted.
- Patient quality of life [ Time Frame: 9 months after study enrollment ]This outcome will be assessed using a validated questionnaire- Short-form 12 version 2 (SF-12v2)
- Patient satisfaction with the service [ Time Frame: 9 months after study enrollment ]Patient and provider satisfaction with the service will be evaluated using a Satisfaction survey designed specifically for this study
- Patient leakage [ Time Frame: 9 months after study enrollment ]Number of patients who have been admitted to hospitals outside of the Partners network will be assessed by patient self-disclosure at close-out
- PLL switch rate from No to Yes-Payment at the end of the study. [ Time Frame: 9 months after study enrollment ]The PLL switch rate from No to Yes-Payment will be evaluated at the end of the study by using the billing accounts from Phillips
- Total number of hospital admissions assessed by reviewing the medical record [ Time Frame: 9 months after study enrollment ]Total number of hospital admissions for participants
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03126565
|United States, Massachusetts|
|Partners Healthcare at Home|
|Waltham, Massachusetts, United States, 02451|
|Principal Investigator:||Kamal Jethwani, MD, MPH||Massachusetts General Hospital|